Literature DB >> 16416060

[Management of diabetes mellitus in patients with angiopathies].

T Lohmann1.   

Abstract

Nowadays, about 6-8% of the German population suffers from diabetes mellitus mostly type 2 but in patients with angiopathies about 30% have known diabetes and a further 30% have newly diagnosed diabetes or impaired glucose tolerance. Therefore diagnosis and therapy of glucose impairment play a central role for management of these patients. The antidiabetic therapy for secondary prevention of cardiovascular disease has to be embedded in a multifactorial concept with management of hypertension, hyperlipidemia and hypercoagulability. The management of diabetes following guidelines is a stepwise therapy with lifestyle interventions (diet, exercise) and oral drugs or insulin. Metformin has shown favorable outcome in overweight patients if aware of side effects; insulin is a safe drug in multimorbid patients and with planned interventions or operations. We are awaiting the results of multiple endpoint studies with newer antidiabetic drugs which may change our current concept of management of diabetes mellitus in these patients in the near future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16416060     DOI: 10.1007/s00392-005-1408-6

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  10 in total

1.  Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.

Authors:  Andreas Pfützner; Nikolaus Marx; Georg Lübben; Matthias Langenfeld; Daniel Walcher; Thomas Konrad; Thomas Forst
Journal:  J Am Coll Cardiol       Date:  2005-06-21       Impact factor: 24.094

2.  Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study.

Authors:  J Olsson; G Lindberg; M Gottsäter; K Lindwall; A Sjöstrand; A Tisell; A Melander
Journal:  Diabetologia       Date:  2000-05       Impact factor: 10.122

3.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

Authors:  J Tuomilehto; J Lindström; J G Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Laakso; A Louheranta; M Rastas; V Salminen; M Uusitupa
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

4.  Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project.

Authors:  Silvio E Inzucchi; Frederick A Masoudi; Yongfei Wang; Mikhail Kosiborod; Joanne M Foody; John F Setaro; Edward P Havranek; Harlan M Krumholz
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

5.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

6.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

7.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

8.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.